Cocrystal Pharma Inc (COCP)

Currency in USD
1.1503
+0.0103(+0.90%)
Real-time Data·

COCP Financial Summary

Key Ratios

P/E Ratio-1.52
Price/Book15.45
Debt / Equity128.45%
Return on Equity-311.68%
Dividend Yield0.00%
EBITDA-8.95M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
2025
31/12
* In Millions of USD (except for per share items)

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.0000
(+682.40% Upside)

Earnings

Latest Release
Aug 17, 2026
EPS / Forecast
-0.23 / -0.17
Revenue / Forecast
100K / --
EPS Revisions
Last 90 days

FAQ

What were Cocrystal Pharma's earnings for the latest quarter?

The Cocrystal Pharma EPS (TTM) is -0.7588. Cocrystal Pharma reported sales of 0.1050, net income of -3.1640, and EPS of -0.2300 for the latest quarter.

What was Cocrystal Pharma's net income for the latest quarter?

Cocrystal Pharma's net income for the latest quarter was -3.1640.

How did Cocrystal Pharma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 0.2250 million USD in the previous quarter to 0.1050 million USD in the latest quarter, and net income moved from -2.2990 million USD to -3.1640 million USD compared to the previous quarter.

What is Cocrystal Pharma's net profit margin on a TTM basis?

Cocrystal Pharma's trailing twelve months (TTM) net profit margin is -3,011.5151%.

How does Cocrystal Pharma's debt to equity ratio compare to industry standards?

Cocrystal Pharma's total debt-to-equity ratio is 128.4482%.

What is Cocrystal Pharma's return on investment on a TTM basis?

Cocrystal Pharma's trailing twelve months (TTM) return on investment (ROI) is -311.6826%.

How has Cocrystal Pharma's total revenue grown this year?

Cocrystal Pharma's total revenue was 0.2250 million USD in the previous quarter and 0.1050 million USD in the latest quarter.

What is Cocrystal Pharma's gross margin on a TTM basis?

Cocrystal Pharma's trailing twelve months (TTM) gross margin is -1,744.2424%%.

What was Cocrystal Pharma's revenue per share for the latest quarter?

Cocrystal Pharma's revenue per share for the latest quarter was 3.6295.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.